Home > Insider Trading > Filing (0000899243-18-017071)

Filing Details

Accession Number:: 0000899243-18-017071
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-18 18:56:39
Reporting Period:: 2018-06-14

Accepted Time:: 2018-06-18 18:56:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	()	N4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053906	S.a. Group Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1218180	S.c.a. International Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1283968	S.a. Westend	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1340096	Invus Public Equities Advisors, Llc	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1340097	Invus Public Equities, L.p.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1404553	Invus Advisors, L.l.c.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1404570	Invus, L.p.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1460839	Pascal Minne	Rue De L'Industrie 44 Bruxelles C9 B-1000	Yes	No	Yes	No
1460840	Westend Administratiekantoor Stichting	Ijsselburcht 3 Arnhem P7 NL-6825 BS	Yes	No	Yes	No
1522131	S.a. Management International Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-14	9,200	$12.66	2,970,094	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2018-06-18	36,584	$13.06	3,006,678	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	21,321,961	Indirect	See Footnotes
Common Stock	35,402,689	Indirect	See Footnotes

Footnotes

The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
These securities are directly held by Invus Public Equities, L.P.
These securities are directly held by Artal International S.C.A.
These securities are directly held by Invus, L.P.
Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.